Haleon Plc - ADR [HLN] vs United Therapeutics [UTHR] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Haleon Plc - ADR wins in 4 metrics, United Therapeutics wins in 15 metrics, with 0 ties. United Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricHaleon Plc - ADRUnited TherapeuticsBetter
P/E Ratio (TTM)19.9316.92United Therapeutics
Price-to-Book Ratio5.082.68United Therapeutics
Debt-to-Equity Ratio53.410.00United Therapeutics
PEG Ratio21.361.77United Therapeutics
EV/EBITDA33.8610.11United Therapeutics
Profit Margin (TTM)13.81%40.36%United Therapeutics
Operating Margin (TTM)22.21%45.64%United Therapeutics
EBITDA Margin (TTM)22.21%45.64%United Therapeutics
Return on Equity9.38%19.30%United Therapeutics
Return on Assets (TTM)4.61%12.96%United Therapeutics
Free Cash Flow (TTM)$2.67B$1.08BHaleon Plc - ADR
Dividend Yield1.63%N/AN/A
1-Year Return-14.37%24.59%United Therapeutics
Price-to-Sales Ratio (TTM)3.636.37Haleon Plc - ADR
Enterprise Value$119.46B$16.14BHaleon Plc - ADR
EV/Revenue Ratio8.075.24United Therapeutics
Gross Profit Margin (TTM)55.38%89.03%United Therapeutics
Revenue per Share (TTM)$2$69United Therapeutics
Earnings per Share (Diluted)$0.45$25.12United Therapeutics
Beta (Stock Volatility)0.240.62Haleon Plc - ADR
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Haleon Plc - ADR vs United Therapeutics Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Haleon Plc - ADR-1.44%1.83%-9.02%-13.45%-12.60%-5.93%
United Therapeutics1.20%4.24%9.54%50.21%42.01%23.10%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Haleon Plc - ADR-14.37%45.81%19.84%19.84%19.84%19.84%
United Therapeutics24.59%114.46%326.34%258.80%694.13%1,312.23%

News Based Sentiment: Haleon Plc - ADR vs United Therapeutics

Haleon Plc - ADR

News sentiment data is not available for Haleon Plc - ADR at this time.

United Therapeutics

News based Sentiment: MIXED

September was a pivotal month for United Therapeutics, marked by the highly positive TETON-2 trial results for Tyvaso in IPF, which drove significant stock gains and analyst upgrades. However, substantial insider selling and ongoing legal battles with Liquidia create a mixed investment picture, requiring careful monitoring of both the opportunities and risks.

View United Therapeutics News Sentiment Analysis

Performance & Financial Health Analysis: Haleon Plc - ADR vs United Therapeutics

MetricHLNUTHR
Market Information
Market Cap i$41.72B$19.33B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i9,529,570924,001
90 Day Avg. Volume i8,844,817904,024
Last Close$8.88$443.44
52 Week Range$8.71 - $11.42$266.98 - $444.57
% from 52W High-22.24%-0.25%
All-Time High$11.42 (Jun 02, 2025)$444.57 (Oct 02, 2025)
% from All-Time High-22.24%-0.25%
Growth Metrics
Quarterly Revenue Growth-0.01%0.12%
Quarterly Earnings Growth0.33%0.11%
Financial Health
Profit Margin (TTM) i0.14%0.40%
Operating Margin (TTM) i0.22%0.46%
Return on Equity (TTM) i0.09%0.19%
Debt to Equity (MRQ) i53.410.00
Cash & Liquidity
Book Value per Share (MRQ)$1.77$158.65
Cash per Share (MRQ)$0.08$67.41
Operating Cash Flow (TTM) i$3.34B$1.37B
Levered Free Cash Flow (TTM) i$2.58B$811.05M
Dividends
Last 12-Month Dividend Yield i1.63%N/A
Last 12-Month Dividend i$0.17N/A

Valuation & Enterprise Metrics Analysis: Haleon Plc - ADR vs United Therapeutics

MetricHLNUTHR
Price Ratios
P/E Ratio (TTM) i19.9316.92
Forward P/E i21.3615.25
PEG Ratio i21.361.77
Price to Sales (TTM) i3.636.37
Price to Book (MRQ) i5.082.68
Market Capitalization
Market Capitalization i$41.72B$19.33B
Enterprise Value i$119.46B$16.14B
Enterprise Value Metrics
Enterprise to Revenue i8.075.24
Enterprise to EBITDA i33.8610.11
Risk & Other Metrics
Beta i0.240.62
Book Value per Share (MRQ) i$1.77$158.65

Financial Statements Comparison: Haleon Plc - ADR vs United Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)HLNUTHR
Revenue/Sales i$3.72B$794.40M
Cost of Goods Sold i$1.66B$92.50M
Gross Profit i$2.06B$701.90M
Research & Development i$105.17M$149.00M
Operating Income (EBIT) i$471.91M$382.80M
EBITDA i$488.09M$449.40M
Pre-Tax Income i$388.31M$423.50M
Income Tax i$88.99M$101.30M
Net Income (Profit) i$299.32M$322.20M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)HLNUTHR
Cash & Equivalents i$911.46M$1.90B
Total Current Assets i$5.59B$3.94B
Total Current Liabilities i$6.42B$721.50M
Long-Term Debt i$10.30BN/A
Total Shareholders Equity i$21.57B$6.81B
Retained Earnings i$36.76B$7.54B
Property, Plant & Equipment i$2.52B$0

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)HLNUTHR
Operating Cash Flow iN/A$463.80M
Capital Expenditures iN/A$-74.90M
Free Cash Flow iN/A$386.30M
Debt Repayment iN/A$-100.00M
Common Stock Repurchase iN/A$0

Short Interest & Institutional Ownership Analysis

MetricHLNUTHR
Shares Short i15.71M2.78M
Short Ratio i1.933.12
Short % of Float i0.00%0.08%
Average Daily Volume (10 Day) i9,529,570924,001
Average Daily Volume (90 Day) i8,844,817904,024
Shares Outstanding i12.25B44.83M
Float Shares i8.99B42.01M
% Held by Insiders i0.00%0.02%
% Held by Institutions i0.13%1.00%

Dividend Analysis & Yield Comparison: Haleon Plc - ADR vs United Therapeutics

MetricHLNUTHR
Last 12-Month Dividend i$0.17N/A
Last 12-Month Dividend Yield i1.63%N/A
3-Year Avg Annual Dividend i$0.11N/A
3-Year Avg Dividend Yield i0.91%N/A
3-Year Total Dividends i$0.34N/A
Ex-Dividend DateApr 25, 2025N/A